TwinBeech Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

TwinBeech Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,954	Closed	-$355K	–	630
2026 Q1	$355K	Sell	16,954 -83,198	-83%	-$1.87M	0.04%	417
2025 Q4	$2.3M	Buy	+100,152	New	+$3.29M	0.16%	171
2025 Q3	–	Sell	-10,789	Closed	-$392K	–	784
2025 Q2	$392K	Sell	10,789 -84,615	-89%	-$3.05M	0.01%	523
2025 Q1	$3.45M	Buy	95,404 +61,547	+182%	+$2.56M	0.06%	306
2024 Q4	$1.42M	Buy	33,857 +28,497	+532%	+$1.41M	0.02%	354
2024 Q3	$298K	Sell	5,360 -12,453	-70%	-$634K	0.01%	617
2024 Q2	$732K	Buy	+17,813	New	+$761K	0.01%	425
2022 Q4	–	Sell	-110,066	Closed	-$4.56M	–	894
2022 Q3	$4.56M	Buy	+110,066	New	+$5.66M	0.12%	205
2021 Q3	–	Sell	-17,927	Closed	-$1.71M	–	724
2021 Q2	$1.71M	Buy	+17,927	New	+$1.87M	0.21%	147
2021 Q1	–	Sell	-6,830	Closed	-$945K	–	639
2020 Q4	$945K	Buy	+6,830	New	+$810K	0.15%	184

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

TwinBeech Capital's RARE Position: Q2 2026 in Review

TwinBeech Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 16,954 shares — an estimated $355K sold.

TwinBeech Capital first reported a position in RARE in Q4 2020 and held it in 10 quarters. The position peaked at $4.56M in Q3 2022. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

TwinBeech Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
TwinBeech Capital sold 16,954 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $355K.
TwinBeech Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 10 quarters.
TwinBeech Capital's Ultragenyx Pharmaceutical position peaked at $4.56M in Q3 2022.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.